Investor Presentaiton

Investor presentation First three months of 2017 Slide 88 Competitive US label for SaxendaⓇ SaxendaⓇ approved in the US for chronic weight management in individuals with a BMI ≥30, or ≥27 in the presence of at least one weight-related comorbidity¹ Profile GLP-1 receptor agonist - a physiological regulator of appetite and calorie intake SaxendaⓇ is the first and only GLP-1 receptor agonist approved for weight management Effect on body weight Effect on comorbidities Safety • 9 in 10 lose weight and 1 in 3 people lose more than 10% of their body weight² Average weight loss of 9.2% in completers at one year² Improvements in cardiometabolic risk factors such as hypertension and dyslipidaemia Boxed warning on thyroid C-cell tumours Precautions on acute pancreatitis, acute gallbladder disease, serious hypoglycaemia³, heart rate increase, renal impairment, hypersensitivity and suicidal ideation 1 Examples include hypertension, type 2 diabetes and dyslipidemia 2 SaxendaⓇ US Package Information. 3 When used with an insulin secretagogue changing diabetes novo nordisk

View entire presentation